Inspire Medical Systems (INSP) Expected to Announce Earnings on Wednesday

Inspire Medical Systems (NYSE:INSP) is projected to announce its Q4 2025 results after the market closes on Wednesday, February 11th. Analysts expect the company to announce earnings of $0.70 per share and revenue of $264.0190 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 11, 2026 at 5:00 PM ET.

Inspire Medical Systems (NYSE:INSP) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.38 EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.53. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The firm had revenue of $224.50 million for the quarter, compared to analysts’ expectations of $220.39 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The business’s revenue for the quarter was up 10.5% on a year-over-year basis. On average, analysts expect Inspire Medical Systems to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Inspire Medical Systems Trading Down 1.9%

Shares of INSP opened at $72.06 on Wednesday. The company has a market cap of $2.09 billion, a price-to-earnings ratio of 49.02, a P/E/G ratio of 7.41 and a beta of 0.74. The business’s fifty day simple moving average is $103.51 and its two-hundred day simple moving average is $94.05. Inspire Medical Systems has a 12 month low of $70.77 and a 12 month high of $203.12.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on INSP shares. Weiss Ratings restated a “sell (d)” rating on shares of Inspire Medical Systems in a research report on Monday, December 29th. Mizuho lifted their price target on shares of Inspire Medical Systems from $110.00 to $130.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Truist Financial lowered Inspire Medical Systems from a “buy” rating to a “hold” rating and set a $96.00 price objective for the company. in a research note on Thursday, January 22nd. Oppenheimer cut Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a report on Thursday, January 22nd. Finally, Wells Fargo & Company lowered their target price on Inspire Medical Systems from $160.00 to $145.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 14th. Eight analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Inspire Medical Systems currently has an average rating of “Hold” and a consensus price target of $133.47.

Insider Activity at Inspire Medical Systems

In other news, Director Shawn Mccormick sold 2,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $127.48, for a total value of $254,960.00. Following the completion of the transaction, the director owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This represents a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its holdings in Inspire Medical Systems by 5,300.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,080 shares of the company’s stock valued at $80,000 after buying an additional 1,060 shares in the last quarter. XTX Topco Ltd lifted its holdings in shares of Inspire Medical Systems by 4.3% in the third quarter. XTX Topco Ltd now owns 7,289 shares of the company’s stock worth $541,000 after buying an additional 300 shares in the last quarter. Voleon Capital Management LP bought a new position in shares of Inspire Medical Systems during the third quarter worth $5,826,000. Verition Fund Management LLC grew its stake in Inspire Medical Systems by 336.3% during the third quarter. Verition Fund Management LLC now owns 71,695 shares of the company’s stock valued at $5,320,000 after acquiring an additional 55,261 shares in the last quarter. Finally, Vestal Point Capital LP purchased a new position in Inspire Medical Systems during the third quarter valued at $10,017,000. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.